This webinar will be a case-based educational webinar that transitions naturally into discussion of current evidence and future implementation of HPIs.
ICHS Members: Complimentary (Log in first for this option.)
Complimentary: early career and global access attendees.
Non-members: $25USD - includes a one year ICHS membership.
Click here to check the time for your location.
Join ICHS for an interactive, case-based webinar where real-world scenarios set the stage for a dynamic discussion on the latest evidence and the outlook of Helicase Primase Inhibitors (HPIs). This session will reflect the evolution of the field with the future introduction of HPIs, the available clinical evidence, and how these therapies may be integrated into future practice.
Dr. Roy Chemaly will facilitate a moderated discussion with the presenters to provide attendees with both the scientific rationale and the clinical context for incorporating HPIs into future management strategies for Refractory HSV in immunocompromised patients.
During the webinar we will:
Webinar Agenda includes:
Whether you are looking to sharpen your clinical reasoning or stay ahead of emerging trends, this session offers evidence driven insight and actionable takeaways.
Reserve your spot today and be part of the conversation shaping tomorrow’s HPI landscape.
Faculty (click here for Faculty Bios)
Dr. Roy F. Chemaly UT MD Anderson Cancer Center
Dr. Camille Kotton Massachusetts General Hospital Harvard Medical School
Dr. Genovefa (Zenia) Papanicolaou Memorial Sloan-Kettering Cancer Center Weill Cornell Medical College
Dr. Joseph Sassine OU College of Medicine University of Oklahoma
